EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Biotechnology in the Development of Gene-Silencing Therapies

Olivia Harrison, Marcus Lee

American Journal of Biotechnology · 31.12.2025 · 6 (6) · 11-15

DOI: 10.71465/ajbt3492 ↗

Kurz gefasst

Fachartikel in der Zeitschrift American Journal of Biotechnology, online erschienen am 31.12.2025. Verfasst von Olivia Harrison und 1 weiteren Autor:innen. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Gene-silencing therapies, particularly RNA interference (RNAi) and CRISPR/Cas-based approaches, represent a promising class of therapeutic strategies aimed at modulating gene expression for the treatment of genetic diseases. Biotechnology has played a crucial role in the development of these therapies by advancing the understanding of molecular mechanisms of gene regulation, as well as improving delivery systems and safety profiles. This article explores the biotechnological innovations driving the development of gene-silencing therapies, including RNAi, CRISPR/Cas9, and antisense oligonucleotides, as well as their applications in treating genetic disorders. We also discuss the challenges in clinical implementation, regulatory considerations, and future prospects for gene-silencing therapies.

Zitieren

APA

Harrison, O., & Lee, M. (2025). Biotechnology in the Development of Gene-Silencing Therapies. American Journal of Biotechnology, 6(6), 11-15. https://doi.org/10.71465/ajbt3492

Vancouver

Harrison O, Lee M. Biotechnology in the Development of Gene-Silencing Therapies. American Journal of Biotechnology. 2025;6(6):11-15. doi:10.71465/ajbt3492

BibTeX
@article{Harrison2025,
  author = {Harrison, Olivia and Lee, Marcus},
  title = {Biotechnology in the Development of Gene-Silencing Therapies},
  journal = {American Journal of Biotechnology},
  year = {2025},
  volume = {6},
  number = {6},
  pages = {11--15},
  doi = {10.71465/ajbt3492}
}
Kostenlos starten →